Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

CaDAnCe-104, an ongoing, open-label, phase 1b/2 master protocol study of Bruton tyrosine kinase degrader BGB-16673 in combination with other agents in patients with relapsed/refractory B-cell malignancies

View Full Paper
Ask AI
Bookmark
Share

Authors

MSMohamed ShanavasThe University of QueenslandJCJulio C. ChávezJacksonville CollegeYTYanhong TongNortheast Normal University

Discussion

Loading...

Member takes

Implication

Open-label trial evaluates safety and efficacy of BGB-16673 with other agents in relapsed B-cell malignancies, suggesting potential for improved outcomes.

Key Points

  • Evaluate the safety and efficacy of BGB-16673 in combination with other agents in patients with relapsed/refractory B-cell malignancies.
  • Open-label, multicenter, phase 1b/2 study across 49 sites
  • Includes patients with relapsed/refractory B-cell malignancies like CLL and FL
  • Analyzes safety/tolerability using NCI-CTCAE and recommends dosage
  • Secondary endpoints assess overall response rate and pharmacokinetics
  • BGB-16673 shows antitumor activity in relapsed/refractory CLL and other B-cell malignancies
  • Expected to identify optimal combinations for enhanced efficacy
  • Assessment of prognostic biomarkers may yield insights into treatment response

Cite This Study

Shanavas et al. (2025) studied this question.

synapsesocial.com/papers/693624d74fa91c937236d0b4https://doi.org/10.1182/blood-2025-1839
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Preliminary efficacy and safety of the Bruton tyrosine kinase degrader BGB-16673 in patients with relapsed/refractory Richter transformation: Results from the ongoing phase 1 CaDAnCe-101 study2025 · 1 citations
  2. 2CaDAnCe-304, a phase 3, open-label, randomized study to evaluate the safety and efficacy of Bruton tyrosine kinase degrader BGB-16673 compared with pirtobrutinib in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma2025 · 1 citations
  3. 3CaDAnCe-302, a phase 3, open-label, randomized study of BGB-16673 compared with idelalisib + rituximab (R), bendamustine + R, or venetoclax + R re-treatment in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma previously exposed to both a BTK and BCL2 inhibitor2025
  4. 4Updated efficacy and safety results of the Bruton tyrosine kinase degrader BGB-16673 in patients with relapsed/refractory indolent non-Hodgkin lymphoma from the ongoing phase 1 CaDAnCe-101 study2025
  5. 5Updated efficacy and safety results of the Bruton tyrosine kinase degrader BGB-16673 in patients with relapsed/refractory Waldenström macroglobulinemia from the ongoing phase 1 CaDAnCe-101 study2025 · 2 citations